Differences in prescription patterns between real-world outpatients with bipolar I and II disorders in the MUSUBI survey
| Autor: | Norio Yasui-Furukori, Masaki Kato, Kazuhira Miki, Takashi Tsuboi, Reiji Yoshimura, Toshiaki Kikuchi, Yukihisa Kubota, Koichiro Watanabe, Seiji Hongo, Kazutaka Shimoda, Eiichiro Goto, Eiichi Katsumoto, Naoto Adachi, Atsuo Nakagawa, Hitoshi Ueda, Koji Edagawa, Takaharu Azekawa, Masataka Shinozaki |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Bipolar Disorder chemistry.chemical_compound Bipolar II disorder Escitalopram Pharmacotherapy Antimanic Agents Internal medicine Outpatients Humans Medicine Duloxetine Bipolar disorder Medical prescription General Psychology business.industry General Medicine medicine.disease Psychiatry and Mental health Prescriptions Mood chemistry business Psychotropic Agent Antipsychotic Agents medicine.drug |
| Zdroj: | Asian Journal of Psychiatry. 67:102935 |
| ISSN: | 1876-2018 |
| Popis: | OBJECTIVE There is limited information available on the prescription of psychotropic agents to patients with bipolar I (BD-I) and bipolar II disorder (BD-II). The purpose of this study was to investigate the characteristics of drug therapy in BD-I and BD-II outpatients, particularly with regard to antidepressants. METHODS In 2017, the MUlticenter treatment SUrvey for BIpolar disorder in Japanese psychiatric clinics (MUSUBI) study collected data on current mental status, medications, and other factors from 2774 outpatients with BD-I or BD-II. RESULTS There were significant differences in the rates of prescriptions for mood stabilizers, antipsychotics and antidepressants. Mood stabilizers and antipsychotics were prescribed at higher rates to patients with BD-I (mood stabilizers; BD-I 86.0%, BD-II 80.8%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect